Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 493

1.
2.

Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.

Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD.

Int J Antimicrob Agents. 2014 Feb;43(2):179-83. doi: 10.1016/j.ijantimicag.2013.10.017. Epub 2013 Nov 18.

PMID:
24315788
4.

Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.

Song KH, Kim HB, Kim HS, Lee MJ, Jung Y, Kim G, Hwang JH, Kim NH, Kim M, Kim CJ, Choe PG, Chung JY, Park WB, Kim ES, Park KU, Kim NJ, Kim EC, Oh MD.

Int J Antimicrob Agents. 2015 Dec;46(6):689-95. doi: 10.1016/j.ijantimicag.2015.09.010. Epub 2015 Oct 17.

PMID:
26555059
5.
7.

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K.

Antimicrob Agents Chemother. 2008 Sep;52(9):3315-20. doi: 10.1128/AAC.00113-08. Epub 2008 Jun 30.

8.

Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.

Yeh YC, Yeh KM, Lin TY, Chiu SK, Yang YS, Wang YC, Lin JC.

J Microbiol Immunol Infect. 2012 Jun;45(3):214-20. doi: 10.1016/j.jmii.2011.11.006. Epub 2012 May 7.

9.

Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.

Kan LP, Lin JC, Chiu SK, Yeh YC, Lin TY, Yang YS, Wang YC, Wang NC, Yeh KM, Chang FY.

J Microbiol Immunol Infect. 2014 Feb;47(1):15-22. doi: 10.1016/j.jmii.2012.08.015. Epub 2012 Oct 3.

10.

Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.

Kullar R, Davis SL, Levine DP, Rybak MJ.

Clin Infect Dis. 2011 Apr 15;52(8):975-81. doi: 10.1093/cid/cir124.

PMID:
21460309
11.

[Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].

Lepe JA, Gil-Navarro MV, Santos-Rubio MD, Bautista J, Aznar J.

Rev Esp Quimioter. 2010 Mar;23(1):43-7. Spanish.

12.

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Moise PA, Sakoulas G, Forrest A, Schentag JJ.

Antimicrob Agents Chemother. 2007 Jul;51(7):2582-6. Epub 2007 Apr 23.

13.

Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence.

Forstner C, Dungl C, Tobudic S, Mitteregger D, Lagler H, Burgmann H.

Clin Microbiol Infect. 2013 Jul;19(7):E291-7. doi: 10.1111/1469-0691.12169. Epub 2013 Mar 13.

14.

Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.

Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, Tsuchida T, Uchino M, Ikeuchi H.

J Infect Chemother. 2011 Feb;17(1):52-7. doi: 10.1007/s10156-010-0086-0. Epub 2010 Jul 13.

PMID:
20625789
15.

Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.

Joo J, Yamaki J, Lou M, Hshieh S, Chu T, Shriner KA, Wong-Beringer A.

Clin Ther. 2013 Jul;35(7):995-1004. doi: 10.1016/j.clinthera.2013.05.018. Epub 2013 Jul 2.

PMID:
23829982
16.

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ.

Clin Pharmacokinet. 2004;43(13):925-42.

PMID:
15509186
17.

Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.

Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, Bauer K, Goff DA, Adamson R, Leuthner K, Virata MD, McKinnell JA, Chaudhry SB, Eskandarian R, Lodise T, Reyes K, Zervos MJ.

Clin Ther. 2016 Jan 1;38(1):16-30. doi: 10.1016/j.clinthera.2015.09.017. Epub 2015 Nov 14.

PMID:
26585355
19.

Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.

Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ.

Pediatr Infect Dis J. 2009 May;28(5):398-402. doi: 10.1097/INF.0b013e3181906e40.

20.

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A.

Arch Intern Med. 2006 Oct 23;166(19):2138-44.

PMID:
17060545

Supplemental Content

Support Center